David Sinclair to Test Rejuvenation Drugs in the XPrize Competition

David Sinclair, a prominent gerontologist at Harvard, has announced a plan to test drugs that he says can rejuvenate the entire body. The trials will take place as part of XPrize, an innovation platform that funds projects aimed at solving humanity's biggest problems.

A vision without disease

Sinclair has long talked about transforming medicine. In his view, within the next two to three decades a doctor's visit will end not with a prescription for disease drugs, but with a prescription for rejuvenation drugs, as prevention of aging. This is not science fiction, he argues, but the next wave of pharmacology.

The idea is simple: if you rejuvenate the whole body, diseases simply will not develop.

How XPrize works for longevity

The rejuvenation competition attracts the world's best researchers. Its distinguishing feature is that funding does not flow through traditional academic channels but through a competition system.

• The winner is whoever proves results in practice, not in theory
• Deadlines are tight, pressure is high, and the prizes are substantial
• Teams from different countries and disciplines take part
• Trials are conducted on volunteers under controlled conditions

Breakthroughs of recent years

Sinclair has plenty of reasons for optimism. Recent years have brought real discoveries: senolytic drugs (which kill "aging" cells) have been identified, and new approaches based on epigenetics and reprogramming have been developed. Companies such as Unity Biotechnology and Calico are already testing these treatments in people, with cautious but positive results. NAD boosters, sirtuins, aging inhibitors: this whole arsenal is ready to leave the lab.

However, leaping from treating individual symptoms of aging to fully rejuvenating the entire body is a difference of scale. Sinclair understands the difficulty and is taking on the challenge through XPrize, where the stakes and the spotlight on results sharpen the focus.

What this means

If the experiment succeeds, it will reshape the entire longevity market. The field will move from the realm of biohackers into the mainstream of the pharmaceutical industry, and for the average person it means that in a couple of decades, doctors' prescriptions will change radically.